Abstract | Background: Case Description: We present a case of a 30-year-old man who was admitted to hospital with several months of cough and the chest computed tomography (CT) scan showed a mass about 2.6 cm × 2.1 cm in the left lung. Then he was diagnosed with lung adenocarcinoma (LUAD). Next generation sequencing (NGS) revealed that he harbors ROS1 fusion and NBN germline mutation. So, he received platinum-based chemotherapy and ROS1 inhibitors, but the disease continued to progress. Ultimately, the patient was switched to sintilimab combined with niraparib and the efficacy was evaluated as stable disease (SD), with a progression-free survival (PFS) of more than 12 months, and the overall survival (OS) is 23 months up to now. During the treatment, the major adverse events (AEs) observed were lymphopenia, nausea, vomiting, and edema. The AEs were tolerable. Conclusions: This case shows that the combination of small-molecule inhibitors and immunotherapy may improve survival in NSCLC patients with driver genes, and sintilimab combined with niraparib provides a successful clinical case for the treatment of refractory tumors HRR gene mutation, which can be used as a reference for personalized treatment. Of course, more clinical trials are needed to confirm this combination treatment strategy.
|
Authors | Fangye Xu, Chunmei Xiao, Weijie Sun, Yuange He, Roberto Chalela, Ken Masuda, Paola Ulivi, Kai Shen, Qianwen Shao, Jiali Xu, Lianke Liu |
Journal | Annals of translational medicine
(Ann Transl Med)
Vol. 10
Issue 16
Pg. 912
(Aug 2022)
ISSN: 2305-5839 [Print] China |
PMID | 36111030
(Publication Type: Case Reports)
|
Copyright | 2022 Annals of Translational Medicine. All rights reserved. |